Founded in 2001, Axience is a reference French specialist vet laboratory offering a comprehensive portfolio of pharma and OTC products mainly for pets. 

Thanks to an excellent market knowledge and a great proximity with veterinarians, Axience offers differentiated solutions targeting niche subscale segments only marginally covered by large pharmaceutical companies, but indispensable to the on-field needs of veterinarians. 

As a true innovation platform, Axience develops internally most of its products and distributes them to 6,500 veterinary clinics across France through its on-field sales force composed of 25 technical sales representatives.

In February 2024, Motion Equity Partners invested in Axience Group alongside its founder, with the ambition to help the Group become the European reference laboratory in animal health specialty solutions